glp-1 nafld Receptor Agonist and Non-Alcoholic Fatty Liver Disease Therapeutic Approach to NAFLD-NASH |

Following FDA review and potential European Medicines Agency approval, new pills could be available by late 2025 or 2026

Mean weight loss ranged from ~6.0% to ~10.8% depending on dose, compared with ~3% in the placebo arm

Follow-up and Monitoring: Commit to regular check-ins with your medical team to track your results, adjust your dosage as needed, and ensure your health remains the top priority

Fever above 102F also warrants prompt evaluation

Lets break down some potential scenarios and what we know so far: If you have IBS-D (diarrhoea-predominant): Slowing down gastrointestinal transit could actually be beneficial in this case

Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype